Stocktoria
Harmony Biosciences Holdings, Inc. HRMY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-08-19
Harmony Biosciences Holdings, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M |
| R&D expense | $189.6M | $145.8M | $76.1M | $70.9M | $30.4M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M |
| Interest expense | — | — | $23.8M | $18.8M | $24.2M |
| Income tax | $56.4M | $46.3M | $44.5M | -$76.8M | $2.8M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M |
| EPS (diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 |
| Operating cash flow | $348.2M | $219.8M | $219.4M | $144.5M | $98.6M |
| Free cash flow | $347.9M | $218.7M | $219.1M | $144.3M | $98.3M |
| Cash & equivalents | $752.5M | $453.0M | $311.7M | $243.8M | $234.3M |
| Inventory | $5.4M | $7.2M | $5.4M | $4.3M | $4.4M |
| Total assets | $1.3B | $999.2M | $811.4M | $673.9M | $433.4M |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M |
| Shareholders' equity | $870.2M | $659.2M | $467.0M | $402.8M | $186.5M |
Source: SEC EDGAR filings · CIK 0001802665 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.